Xlear filed a Pre-Emergency Use Authorization (Pre-EUA) Request with the FDA in December, comparing the use of nasal spray to handwashing and suggesting it could be used as part of a layered approach to combating the spread of the virus. While more research and data is needed, there are some promising results coming from initial studies.
Xlear’s Pre-EUA Request is based on initial data suggesting Xlear Nasal Spray may reduce SARS-CoV-2 viral load in the nose, and otherwise attenuate the virus.
“Studies show that regular nasal cleansing may help reduce viral infections, including from the SARS-CoV-2 virus (COVID-19),” said Dr. Gustavo Ferrer, a doctor and global respiratory disease expert who has studied the use of Xlear Nasal Spray to combat SARS-CoV-2.
Xylitol has been shown to have inhibitory properties versus SARS-CoV-2 in cell culture, in vitro according to another study.
Xylitol is one of the ingredients of Xlear Nasal Spray and is also found in a wide variety of oral care products.
Xlear has been used by millions of people over the last twenty years for cleansing and moisturizing the nasal cavities without a single report of a significant adverse event. Now it may prove to be useful for more than just oral care.
